克拉-1的表达预测了晚期喉癌的复发和治疗反应:一个潜在的治疗目标
Eun Kyung Jung1, S M Abdus Salam2,3, Hye-Bin Jang1
1Department of Otolaryngology-Head and Neck Surgery, Chonnam National University Medical School and Hwasun Hospital, Gwangju 58128, Republic of Korea.
Current oncology (Toronto, Ont.)
|September 26, 2025
概括
氨酸-1 (KRT1) 基因表达在复发的晚期喉癌中较高. KRT1可以预测复发,并作为头部和部状细胞癌的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 晚期喉癌的存活率仍然低于最佳水平.
- 确定可靠的复发生物标志物对于改善患者的治疗结果至关重要.
研究的目的:
- 调查氨酸-1 (KRT1) 表达和晚期喉癌复发之间的关联.
- 评估KRT1作为潜在的生物标志物和治疗点.
主要方法:
- RNA测序以识别与复发相关的基因.
- 免疫组织化学评估患者样本中的KRT1表达.
- 在体外研究中,使用人类头部和部状细胞癌 (HNSCC) 细胞系来检查KRT1功能.
主要成果:
- 在复发的喉癌病例中观察到更高的KRT1基因表达.
- 有KRT1阳性患者的整体存活率 (OS) 和无复发存活率 (RFS) 趋势较差.
- KRT1敲击抑制了瘤细胞入侵,迁移和上皮细胞-介质细胞过渡 (EMT) 标志物,同时增强了细胞亡和强化化疗-放射治疗效应.
结论:
- KRT1表达与晚期喉癌复发有关.
- KRT1显示出作为复发的预测生物标志物和治疗点的潜力.
- 需要进一步的研究来阐明KRT1的分子机制和临床实用性,特别是指导并发化疗 (CCRT) 决策.
更多相关视频
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
lncRNA - Long Non-coding RNAs
9.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K


